肿瘤细胞治疗研究
英文原题：Human NKG2C(+) adaptive NK cells for Cancer immunotherapy.
自然杀伤（NK）细胞是固有免疫系统的关键组成部分，在肿瘤免疫监视中发挥关键作用。
自然杀伤（NK）细胞是固有免疫系统的关键组成部分，在肿瘤免疫监视中发挥核心作用。近年来，由人巨细胞病毒（HCMV）感染诱导的一类NKG2C+适应性NK细胞亚群因其独特的内存样特性而受到广泛关注。该亚群在血液系统恶性肿瘤和实体瘤的临床前模型中已展现出显著的治疗潜力，并且在急性髓系白血病（AML）和卵巢癌的早期临床试验中显示出良好的安全性特征及初步疗效迹象。通过应用“超级供者”筛选策略，并将NKG2C特异性激活与细胞因子刺激相结合，可实现NKG2C+适应性NK细胞的高效体外扩增。当进一步整合合成免疫学方法——如NK细胞衔接器（NKCEs）或工程化受体——以及表观遗传调控和代谢重编程时，该亚群的抗肿瘤功能可得到全面增强。这些进展有望释放其治疗潜力，并为下一代癌症免疫治疗提供新方向和范式。
Natural killer (NK) cells are key components of the innate immune system and play a pivotal role in tumor immunosurveillance. In recent years, a subset of NKG2C + adaptive NK cells induced by human cytomegalovirus (HCMV) infection has attracted considerable attention because of its distinctive memory-like properties. This subset has shown substantial therapeutic potential in preclinical models of both haematological malignancies and solid tumors, and early-phase clinical trials in acute myeloid leukaemia (AML) and ovarian cancer have indicated a favorable safety profile with preliminary signs of efficacy. By applying a "super-donor" selection strategy and combining NKG2C-specific activation with cytokine stimulation, efficient ex vivo expansion of NKG2C + adaptive NK cells can be achieved. When further integrated with synthetic immunology approaches-such as NK cell engagers (NKCEs) or engineered receptors-together with epigenetic modulation and metabolic reprogramming, the antitumor functions of this subset can be comprehensively augmented. These advances may unlock its therapeutic potential and offer new directions and paradigms for next-generation cancer immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
